US-based ophthalmic medical device developer LumiThera closed a $14m series C round that included optics technology manufacturer Nikon Corporation yesterday.
Investment firm WaterStar Capital led the round, which also featured Celeste Management, Imagine Ventures, Keiretsu Capital and Water Star Mercury Fund.
Founded in 2013, LumiThera is developing Valeda Light Delivery System, a non-invasive treatment for age-related macular degeneration (AMD), a condition that causes eye diseases and blindness.
Clark Tedford, LumiThera’s president and CEO, said: “Our soft launch in Europe in the last year has demonstrated excitement for Valeda as the first approved treatment for dry AMD using photobiomodulation.”
The company raised $5.5m in series B funding from WaterStone Capital and RPR Venture in 2017 and $4.5m of series A funding from undisclosed investors the previous year according to Puget Sound Business Journal, and its investors also include Puget Sound Venture Club.
